Recludix Pharma (United States)

Recludix is a clinical-stage company with leading, innovative platform approaches to discover and develop novel inhibitors for the toughest protein targets. The company is developing oral precision medicines for inflammatory diseases, focusing on SH2 domain inhibitors. It is conducting a Phase 1 study of REX-8756, an oral STAT6 inhibitor, in partnership with Sanofi.

Recludix is a clinical-stage company with leading, innovative platform approaches to discover and develop novel inhibitors for the toughest protein targets. The company has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. Recludix is employing this approach first in the development of SH2 domain inhibitors. The company is conducting a Phase 1 study of REX-8756, an oral inhibitor of STAT6, in a strategic development and commercialization partnership with Sanofi. Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs.

1. 1Home - Recludix Pharmarecludixpharma.com
2. 2About Overview - Recludix Pharmarecludixpharma.com
3. 3Recludix Pharma (United States)wikidata.org